Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
HIV-1 capsid | 1 |
DNA helicase/primase complex | 1 |
Target |
Mechanism HIV-1 capsid inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date17 Aug 2022 |
Mechanism DNA helicase/primase complex inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ASK1 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date- |
Sponsor / Collaborator |
Start Date28 Aug 2018 |
Sponsor / Collaborator H. Lundbeck A/S [+2] |
Start Date23 Oct 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lenacapavir Sodium ( HIV-1 capsid ) | HIV Infections More | NDA/BLA |
Pritelivir ( DNA helicase/primase complex ) | Herpes Simplex More | Phase 3 |
Ibodutant ( NK2R ) | Irritable Bowel Syndrome More | Discontinued |
Selonsertib ( ASK1 ) | Hepatitis, Alcoholic More | Pending |